GLAXO AGREEMENT WITH SEQUANA FOR TYPE II DIABETES GENE RESEARCH
Executive Summary
GLAXO AGREEMENT WITH SEQUANA FOR TYPE II DIABETES GENE RESEARCH, announced July 28, is the first major collaboration for the La Jolla, Calif. gene discovery firm. The agreement gives Glaxo access to Sequana Therapeutics' high-throughput analytical systems and advanced bioinformatics to allow the company to "establish a rational strategy for identifying drug targets and develop appropriate therapeutics" for the disease, Glaxo said.